is compound semaglutide fda approved Warns Against Using Compounded FDA warns against using compounded

If you are taking anticoagulants (e.g., warfarin) or antiplatelet medicines, discuss injection technique with your trial team, as you may be at increased risk of bruising or bleeding at the injection site

Additionally, maintaining good overall skin health through adequate hydration and moisturisation can improve skin resilience and reduce susceptibility to injection site reactions

staggered titration Cycle driver GI tolerance sets the pace Tirzepatide Loading 2.5 5 7.5 10 12.5 mg (every 4 weeks) Frequency Once weekly Maintenance 15 mg weekly Route SubQ Cagrilintide Loading Start Week 9: 0.25 0.5 1.0 1.7 mg Frequency Once weekly Maintenance 2.4 mg weekly Route SubQ Weekly Schedule Example (Maintenance Phase) Monday Tirzepatide 15 mg (one site) + Cagrilintide 2.4 mg (different site) Tuesday No injections Wednesday No injections Thursday No injections Friday No injections Saturday No injections Sunday No injections Both compounds are once weekly

Endocrinology (2008) 149(10):517788